2024-04-05 11:50:24 ET
Summary
- Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon.
- The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade.
- Rocket's pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others.
- An updated analysis around Rocket Pharmaceuticals follows in the paragraphs below.
Shares of gene therapy concern Rocket Pharmaceuticals, Inc. ( RCKT ) have risen by 20% since we last looked at it in May of last year, as the company is poised for two potential FDA approvals. Furthermore, its one potential blockbuster rare disease gene therapy, RP-A501 for the treatment of Danon Disease, began enrolling patients in 1H23 after very encouraging Phase 1 results....
Read the full article on Seeking Alpha
For further details see:
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)